A New Frontier in AAT Deficiency Congruence Therapeutics has reached a significant milestone in its pursuit of novel therapies for Alpha-1 Antitrypsin (AAT) deficiency. The company recently announced that it will provide an oral presentation on its lead program, CGX-195, at the prestigious ERS Alpha-1 Antitrypsin (AAT) Conference 2026. Understanding CGX-195 CGX-195 is being developed…